Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results - TheStreet

NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report fell 1.77% to $111.44 in morning trading Wednesday after the biotech company reported third-quarter earnings that came up short of analysts' expectations.

Gilead reported adjusted earnings per share of $1.84, an increase from 52 cents in the third quarter one year ago. Revenue surged to $6.04 billion from $2.78 billion in the same period one year earlier.

The consensus estimate called for EPS of $1.92 on revenue of $5.99 billion.

Must Read:Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead also updated its full-year 2014 guidance and now expects net product sales in the range of $22 million to $23 million, up slightly from its previous guidance in July of $21 million to $23 million. Gilead first issued guidance in the range of $11.3 million to $11.5 million in February.

Image placeholder title

GILD

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.